FATP2 is responsible for arachidonate utilization and prostaglandin 2 synthesis, whereas inhibition of FATP2 expression abrogates immunosuppressive capacity in PMN-MDSCs and enhances the efficacy of cancer immunotherapy (Veglia et al. 2021). This evidence concerns the gene SLC27A2 and cancer.